129 results
Page 4 of 7
6-K
EX-99.3
swqgb7p
8 Nov 21
Securities Purchase Agreement
5:28pm
6-K
EX-99.1
hyknog4bgq v4
8 Nov 21
Securities Purchase Agreement
5:28pm
6-K
f3bydok6 vbz79cs7a
15 Sep 21
Autolus Therapeutics announces the appointment of John H. Johnson as non-executive chairman of its Board of Directors
4:30pm
424B5
708zhj6m
19 Aug 21
Prospectus supplement for primary offering
4:13pm
F-3
EX-23.1
tdg0v30c3fi39mi59a9
6 Aug 21
Shelf registration (foreign)
2:30pm
F-3
EX-4.4
oshwh6z64pj
6 Aug 21
Shelf registration (foreign)
2:30pm
F-3
e2obzpup3g8y 8e5
6 Aug 21
Shelf registration (foreign)
2:30pm
6-K
EX-2
xiiyukfx v01rxa88qbn
30 Jun 21
Annual Report and Accounts
6:05am
6-K
EX-1
wnsw88kgooz6f7hynii
30 Jun 21
Annual Report and Accounts
6:05am
6-K
EX-1.1
dp4d1qhq3socs57x
11 Feb 21
Autolus Announces Proposed Public Offering in the United States
5:18pm
6-K
EX-5.1
vyxzpox8mw83hpkyr m4
11 Feb 21
Autolus Announces Proposed Public Offering in the United States
5:18pm
424B5
w92xre
11 Feb 21
Prospectus supplement for primary offering
5:16pm
424B5
wla8gn1v
8 Feb 21
Prospectus supplement for primary offering
5:27pm
6-K
EX-99.3
urhrvn9ym3k
7 Dec 20
Updated data from the ALLCAR study suggests AUTO1’s potential for transformational activity in adult patients with r/r ALL
4:00pm
6-K
EX-99.2
porvbgmsqs
7 Dec 20
Updated data from the ALLCAR study suggests AUTO1’s potential for transformational activity in adult patients with r/r ALL
4:00pm
424B5
bsyptz0r4 f6hxat
18 Sep 20
Prospectus supplement for primary offering
8:01am
6-K
EX-1.1
8rl4szancr1ok539m8o
18 Sep 20
Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ESMO
7:12am